PRC2 Loss Amplifies RAS-Driven Transcription and Results in Sensitivity to Bromodomain Inhibition

Get Permission

PRC2 (polycomb repressive complex 2) has been shown to promote oncogenesis in many tumor types; however, loss of function mutations in PRC2 components has also been shown to occur in some hematopoietic malignancies, raising questions about the precise role of the complex in cancer.

In a study reported in Nature, De Raedt and colleagues showed that the polycomb group gene SUZ12 functions as a tumor suppressor in peripheral nervous system tumors, high-grade glioma, and melanoma by cooperating with mutations in NF1. Loss of NF1, which encodes a RAS GTPase-activating protein, drives tumorigenesis by activating RAS. Loss of SUZ12 was shown to potentiate the effects of NF1 mutations by amplifying RAS-driven transcription through effects on chromatin. However, inactivation of SUZ12 was also associated with an epigenetic switch that resulted in sensitivity of these cancers to bromodomain inhibitors.

The investigators concluded: “Collectively, these studies not only reveal an unexpected connection between the PRC2 complex, NF1 and RAS, but also identify a promising epigenetic-based therapeutic strategy that may be exploited for a variety of cancers.” ■

De Raedt T, et al: Nature 514:247-251, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.